Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunological characterization of prolonged imiquimod exposure in healthy volunteers
2021-005429-26Phase 2Completed
- Sponsor
- Centre for Human Drug Research
- Start
- Nov 2021
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imiquimod, sponsored by Centre for Human Drug Research. Primary endpoint: Cytokines and immune cells in skin biopsies. Started Nov 2021; status: completed.
02
Drugs
imiquimod
Beyond the preview
Go deeper on 2021-005429-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005429-26.